Literature DB >> 19213773

Clinical relevance of non-tuberculous mycobacteria isolated in the Nijmegen-Arnhem region, The Netherlands.

J van Ingen1, S A Bendien, W C M de Lange, W Hoefsloot, P N R Dekhuijzen, M J Boeree, D van Soolingen.   

Abstract

BACKGROUND: The frequency of clinical isolation of non-tuberculous mycobacteria (NTM) in the Netherlands is increasing, but its clinical relevance is often uncertain.
OBJECTIVE: To assess the frequency and clinical relevance of isolation of NTM in four associated hospitals in a single region in the Netherlands.
METHODS: Medical files of all patients from whom NTM were isolated between January 1999 and January 2005 were reviewed retrospectively. Diagnostic criteria for non-tuberculous mycobacterial disease published by the American Thoracic Society (ATS) were used to determine clinical relevance.
RESULTS: 232 patients were found, from whom NTM were isolated from the respiratory tract in 91% of cases. Patients were mostly white men, with an average age of 60 years and pre-existing pulmonary disease. Fifty-three of 212 patients (25%) with pulmonary isolates met the ATS diagnostic criteria for pulmonary NTM disease; this percentage differed by species. Most patients were treated with rifampicin, ethambutol and clarithromycin. Treatment outcome for pulmonary NTM disease was suboptimal but differed by species: overall, improvement was seen in 67% of treated patients, but in only 50% of those with pulmonary M avium disease. Lymphadenitis was the most common extrapulmonary disease type.
CONCLUSIONS: Twenty-five per cent of all patients with pulmonary NTM isolates met the ATS criteria. Clinical relevance differs by species. NTM isolation increases over time. Species distribution differs from that of neighbouring countries and the M avium complex isolates have traits different from those reported in the USA. Adherence to diagnostic and treatment guidelines can be improved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19213773     DOI: 10.1136/thx.2008.110957

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  71 in total

1.  Mycobacterium avium complex cervical lymphadenitis in an immunocompetent adult.

Authors:  Joshua B Christensen; John Koeppe
Journal:  Clin Vaccine Immunol       Date:  2010-07-28

2.  Relative risk of all-cause mortality in patients with nontuberculous mycobacterial lung disease in a US managed care population.

Authors:  Theodore K Marras; Christopher Vinnard; Quanwu Zhang; Keith Hamilton; Jennifer Adjemian; Gina Eagle; Raymond Zhang; Engels Chou; Kenneth N Olivier
Journal:  Respir Med       Date:  2018-10-22       Impact factor: 3.415

3.  Increasing isolation of rapidly growing mycobacteria in a low-incidence setting of environmental mycobacteria, 1994-2015.

Authors:  F Alcaide; M J Peña; D Pérez-Risco; D Camprubi; L Gonzalez-Luquero; M D Grijota-Camino; J Dorca; M Santin
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2017-03-20       Impact factor: 3.267

4.  Nontuberculous mycobacterial lung infections in Ontario, Canada: clinical and microbiological characteristics.

Authors:  Theodore K Marras; Mauli Mehta; Pamela Chedore; Kevin May; Mohammed Al Houqani; Frances Jamieson
Journal:  Lung       Date:  2010-04-11       Impact factor: 2.584

5.  Matrix-Assisted Laser Desorption Ionization-Time of Flight Mass Spectrometry Fails To Identify Nontuberculous Mycobacteria from Primary Cultures of Respiratory Samples.

Authors:  Kim van Eck; Dirk Faro; Melanie Wattenberg; Arjan de Jong; Saskia Kuipers; Jakko van Ingen
Journal:  J Clin Microbiol       Date:  2016-05-04       Impact factor: 5.948

6.  Randomized Trial of Liposomal Amikacin for Inhalation in Nontuberculous Mycobacterial Lung Disease.

Authors:  Kenneth N Olivier; David E Griffith; Gina Eagle; John P McGinnis; Liza Micioni; Keith Liu; Charles L Daley; Kevin L Winthrop; Stephen Ruoss; Doreen J Addrizzo-Harris; Patrick A Flume; Daniel Dorgan; Matthias Salathe; Barbara A Brown-Elliott; Renu Gupta; Richard J Wallace
Journal:  Am J Respir Crit Care Med       Date:  2017-03-15       Impact factor: 21.405

Review 7.  Repositioning rifamycins for Mycobacterium abscessus lung disease.

Authors:  Uday S Ganapathy; Véronique Dartois; Thomas Dick
Journal:  Expert Opin Drug Discov       Date:  2019-06-14       Impact factor: 6.098

8.  Utility of rpoB gene sequencing for identification of nontuberculous mycobacteria in the Netherlands.

Authors:  Rina de Zwaan; Jakko van Ingen; Dick van Soolingen
Journal:  J Clin Microbiol       Date:  2014-05-07       Impact factor: 5.948

9.  Management of pulmonary nontuberculous mycobacterial disease.

Authors:  Kathleen L Horan; Shawn J Skerrett
Journal:  F1000 Med Rep       Date:  2009-12-15

10.  Increasing reports of non-tuberculous mycobacteria in England, Wales and Northern Ireland, 1995-2006.

Authors:  Jonathan E Moore; Michelle E Kruijshaar; L Peter Ormerod; Francis Drobniewski; Ibrahim Abubakar
Journal:  BMC Public Health       Date:  2010-10-15       Impact factor: 3.295

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.